SUNNYVALE, Calif., Sept.26, 2019 /PRNewswire/ -- Plug and Play today announced the 130 startups selected to participate in their Winter 2019 batches.
Emeryville, CA—May 2019—SCA Robotics(SCA) today announced it has joined the NVIDIA Inception program, which is designed to nurture startups revolutionizing industries with advancements in AI and data sciences.
SCA Robotics is a core technology company building AI medical solutions related to the diagnostics of cancer and other chronic diseases. As a strategic partner to the world-renowned City of Hope Comprehensive Cancer Center in Los Angeles, SCA pioneered the first AI solution related to metastatic and nonmetastatic tumor identification within the brain. SCA has experience working on various AI projects related to diabetes, interventional heart disease,T-cell intervention, and eye disease.
The NVIDIA Inception program provides SCA Robotics with a platform and infrastructure to build cutting-edge computer vision applications as they relate to medicine and other industries. The program assists emerging AI companies, such as SCA Robotics, with the latest AI tools, technology, and deep learning expertise, which are critically needed resources.
SCA Robotics CEO Rob Rao commented, “Thanks to NVIDIA’s tools and resources, the unification of SCA’s AI algorithms with cutting-edge GPU hardware will usher in a paradigm shift in medicine that will revolutionize the way medical care is provided.”
NVIDIA’s Inception program is a virtual accelerator program that helps startups during critical stages of product development, prototyping, and deployment. Every Inception member gets a custom set of ongoing benefits, from hardware grants and marketing support to training with deep learning experts.
SCA Robotics is a high-performing team of computer vision and data analytics experts building Artificial Intelligence medical solutions relating to the diagnostics of cancer and other chronic diseases. As a strategic partner to the world-renowned City of Hope Comprehensive Cancer Center in Los Angeles, SCA pioneered the first AI solution related to metastatic and nonmetastatic tumor identification within the brain. In addition to the COH partnership, SCA has experience with AI projects relating to diabetes, interventional heart disease, T-cell intervention, and vision loss prevention (eye disease). SCA was selected and attended the prestigious American Diabetes Association's 23rd Annual Leaders Forum Healthtech Showcase for its work in AI and diabetes. For additional information or to request a presentation visit
Max Wasilko, VP Business Development
SAN FRANCISCO, CA – NOV 2, 2018 - SCA Robotics, an early stage, commercial Precision Analytics company, developing artificial intelligence (AI) diagnostic solutions proven to improve the identification, prediction, and treatment of patients with cancer, diabetes, and heart disease, made its debut at the annual ADA Leaders Forum Healthtech Showcase.
SCA Robotics founder and CEO Rob Rao remarked, “It is sincerely an honor for us to take part in this year's prestigious event, which has been a long-standing tradition for both the ADA and the Silicon Valley community."
Each year the American Diabetes Association® (ADA) invites life science leaders, business professionals, angel investors, and venture capitalists to come together. The Leaders Forum HealthTech Showcase connects investors and industry experts to healthcare startup companies while benefitting the ADA's mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
Mr. Rao continued and said, "Thanks to the ADA, this was a perfect occasion for SCA to prove to the health and investment community exactly how we make artificial intelligence and machine learning work for health care. In addition to eliminating the most difficult challenges in diabetic medicine, we have proven our ability to determine cancer types, make predictions for brain tumors, and valve replacements needed in the heart.”
Along with a select group of 30 health and technology companies, SCA was invited to demonstrate its proven artificial intelligence solutions utilizing machine learning to predict hypoglycemia and hyperglycemia in patients.
SCA develops diagnostic and clinical analysis solutions designed to investigate and predict patient outcomes based on clinical and computer imaging data ( X-rays, CT scans, Nuclear medicine scans, MRI scans, Ultrasound) with amazing success.
Rob commented further, “The SCA Robotics team is extremely proud of what it has accomplished. Looking forward we are expanding our AI expertise beyond early detection and management of diabetes, and cancer, but also to determine the probability of a valve replacement event in the heart, also known as TAVI prediction."
About SCA Robotics:
Formed in 2017, SCA Robotics is an early stage, commercial Precision Analyticscompany developing artificial intelligence (AI) diagnostic solutions proven to improve the identification, prediction, and treatment of patients with cancer diabetes and heart disease.
SCA's diagnostic and clinical analysis solutions are based on big data, deep learning and medical imaging analysis (computer vision) to investigate clinical and medical imaging data such as X-rays, CT scans, Nuclear medicine scans, MRI scans, Ultrasound. SCA's has proven expertise in developing AI solutions related to metastatic and nonmetastatic tumor prediction, closed-loop glucose monitoring (for medical devices) and clinical and MRI imaging data for cases requiring valve replacement in the heart (TAVI). SCA's mission is to make AI and machine learning work for healthcare building precision medicine solutions to save human lives drastically improves patient initiatives as well as protocol and business operations. All SCA products are delivered via software-as-a-solution (SaaS).
-SCA Robotics is a strategic partner to a major cancer research facility, the City of Hope, to pioneer and develop a "Radiographical Assessment of Brain and Spinal Tumors using Predictive Artificial Intelligence Modeling."
-SCA was selected and attended the prestigious American Diabetes Association's 23rd Annual Leaders Forum Healthtech Showcase in November 2018.
For more information please contact
Max Wasilko @ 203.979.2988 or email@example.com
About the American Diabetes Association
Approximately every 21 seconds, someone in the United States is diagnosed with diabetes. Nearly half of the American adult population has diabetes or prediabetes, and more than 30 million adults and children are living with the disease. The American Diabetes Association (ADA) is the nation's leading voluntary health organization on a mission to prevent and cure diabetes, as well as improve the lives of all people affected by the disease. For nearly 80 years, the ADA has driven discovery by funding research to treat, manage and prevent all types of diabetes, while working relentlessly for a cure. Magnifying the urgency of this epidemic, the ADA works to safeguard policies and programs that protect people with the illness, those at risk of developing diabetes and the health care professionals who serve them by initiating programs, advocacy and education efforts that can lead to improved health outcomes and quality of life. To learn more or to get involved, call 1-800-DIABETES (1-800-342-2383) or visit us at diabetes.org. Information is available in English and Spanish. Join the conversation with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).